Focused preclinical studies with human PDX models with dose-titration of combinations of GHRAs and selected antineoplastic agents and subsequent carefully designed human clinical trials are needed to validate the transformative prognostic potential of targeting GHR in pancreatic cancer. This evidence concerns the gene GHR and pancreatic neoplasm.